文献速递新发突发、热带与寄生虫病

高剂量伊维菌素的安全性:系统综述与荟萃分析

Safety of high-dose ivermectin: a systematic review and meta-analysis.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该系统综述与荟萃分析纳入6项报告患者个体数据的研究,比较标准剂量(≤400 μg/kg)与更高剂量伊维菌素的不良事件。结果显示两组发生不良事件的个体数无差异,严重程度亦无差异;仅一项盘尾丝虫病试验中高剂量组眼部事件增加,均为暂时性轻至中度。作者认为高剂量安全性似与标准剂量相当,但数据不足以支持超批准剂量使用。

要点

  • 高剂量与标准剂量伊维菌素的不良事件发生数无差异。
  • 不良事件严重程度在标准与高剂量间无差异。
  • 盘尾丝虫病患者高剂量组眼部事件增加但短暂轻中度。

核心结论

  • 在本综述范围内高剂量伊维菌素安全性似与标准剂量相当,但数据不足以支持推荐超批准剂量使用。
  • 盘尾丝虫病患者中眼部不良事件虽短暂但仍值得关注。

研究设计与样本

  • 系统文献综述与荟萃分析,纳入报告患者个体数据的研究共6项。
  • 荟萃分析纳入报告剂量≥200与≥400 μg/kg数据的临床试验。

主要发现

  • 系统检索识别6项研究,未发现发生不良事件的个体数存在差异。
  • 多种适应症临床试验的描述性分析显示标准剂量(至400 μg/kg)与更高剂量间不良事件严重程度无差异。
  • 仅一项盘尾丝虫病治疗试验中高剂量组眼部事件增加,均为暂时性且轻至中度。

关键数值与推荐

  • 荟萃分析纳入标准为临床试验报告剂量≥200与≥400 μg/kg的数据。
  • 标准剂量定义为至400 μg/kg。

临床怎么用

  • 现有数据可告知项目管理者并指导评估伊维菌素新用法时的操作研究。
  • 不支持在批准剂量以上常规使用伊维菌素。
  • 盘尾丝虫病患者使用高剂量时需关注眼部不良事件。

局限性

  • 纳入研究仅6项,数据不足以支持超批准剂量推荐。
  • 眼部事件信号主要来自单项盘尾丝虫病试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ivermectin is a key anthelmintic for the control of neglected tropical diseases. The main indications for population-level control with ivermectin through mass drug administration are onchocerciasis and lymphatic filariasis; however, there is interest in using higher, fixed-dose regimens for the control of scabies, soil-transmitted helminths and malaria. Safety data for these higher-dose regimens are needed. METHODS: A systematic literature review and meta-analysis on the safety and doses of ivermectin was conducted. Eligible studies reported patient-level data and, for the meta-analysis, clinical trials reporting data on doses ≥200 and ≥400 μg/kg were included. Incidence ratios were used to compare adverse events by severity and organ system affected. RESULTS: The systematic search identified six studies for inclusion, revealing no differences in the number of individuals experiencing adverse events. A descriptive analysis of these clinical trials for a variety of indications showed no difference in the severity of the adverse events between standard (up to 400 μg/kg) and higher doses of ivermectin. Organ system involvement only showed an increase in ocular events in the higher-dose group in one trial for the treatment of onchocerciasis, all of them transient and mild to moderate in intensity. CONCLUSIONS: Although within this review the safety of high-dose ivermectin appears to be comparable to standard doses, there are not enough data to support a recommendation for its use in higher-than-approved doses. Ocular adverse events, despite being transient, are of concern in onchocerciasis patients. These data can inform programme managers and guide operational research activities as new approaches for the use of ivermectin are evaluated.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Navarro M, Camprubí D, Requena-Méndez A, et al. Safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother. 2020. PMID: 31960060. doi:10.1093/jac/dkz524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。